Siliq Probably Isn't The Light At The End Of Valeant's Tunnel

Valeant is touting Siliq to lead new product growth, but the drug's significant safety concerns in a competitive psoriasis market likely will offset efficacy advantages it could offer.

Valeant Pharmaceuticals International Inc. executives clearly wanted to look on the brighter side of life during their Feb. 28 earnings call, but a launch strategy for recently approved Siliq (brodalumab) based on clinical trial efficacy and saying that other drugs approved for psoriasis present safety issues too isn't likely to produce the sales that the Canadian company needs to reverse its recent decline.

Investors apparently didn't buy into the optimism that CEO Joseph Papa and colleagues were trying to sell on Valeant's fourth...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip